Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Imaging of 111In-IPN01087 in Pancreatic and Colorectal Cancer
NCT04632199Phase 1Withdrawn
- Sponsor
- Ipsen
- Start
- Mar 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of 111in-ipn01087 in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) (2 arms), sponsored by Ipsen. Primary endpoint: Incidence of Treatment-emergent adverse events at 12 months. Planned start Mar 2021; status: withdrawn.
02
Drugs
111in-ipn01087
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04632199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04632199.